How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/osteolytic-lesions-of-multiple-myeloma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osteolytic Lesions of Multiple Myeloma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteolytic Lesions of Multiple Myeloma (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteolytic Lesions of Multiple Myeloma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
pamidronate	pamidronate	US Department of Veterans Affairs		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Hypoxanthine-guanine phosphoribosyltransferase
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Osteolytic Lesions of Multiple Myeloma
Children's Hospital Medical Center, Cincinnati · 1 drug in Osteolytic Lesions of Multiple Myeloma
Novartis · 1 drug in Osteolytic Lesions of Multiple Myeloma
US Department of Veterans Affairs · 1 drug in Osteolytic Lesions of Multiple Myeloma
University of Arkansas · 1 drug in Osteolytic Lesions of Multiple Myeloma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteolytic Lesions of Multiple Myeloma:

Cite this brief

Drug Landscape (2026). Osteolytic Lesions of Multiple Myeloma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteolytic-lesions-of-multiple-myeloma. Accessed 2026-06-10.

Osteolytic Lesions of Multiple Myeloma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing